Resumption of enrollment removes a key regulatory overhang; traders should position ahead of the mid-2026 clinical update as next major catalyst. Watch for protocol refinement details and safety data in upcoming disclosures.
MGNX drugs
MGNX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $3.44entry
- T+1 · 7mo ago +4.65%α +4.71% · $3.60
- T+5 · 7mo ago −0.87%α −4.06% · $3.41
- T+20 · 6mo ago −12.50%α −20.07% · $3.01
- T+60 · 4mo ago +32.85%α +22.07% · $4.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab for gynecologic cancers, allowing resumption of new patient enrollment under a revised protocol. The company remains on track to provide a mid-2026 clinical update.
Key Facts
- FDA lifted the partial clinical hold on the Phase 2 LINNET study of lorigerlimab.
- Enrollment of new patients will resume with additional risk-mitigation measures for hematologic and cardiac toxicities.
- Study evaluates lorigerlimab in platinum-resistant ovarian cancer and clear cell gynecologic cancer with an ORR primary endpoint.
- 41 patients have already been dosed in the LINNET study; over 300 patients dosed across all lorigerlimab trials to date.
- Mid-year 2026 update expected for the program.
Financial Impact
Non-dilutive near-term value catalyst; de-risks lorigerlimab development path
Risk Factors
- Potential for renewed safety concerns given prior hematologic and cardiac toxicities.
- Mid-2026 timeline for data readout implies limited near-term catalysts.
- Market cap remains small ($213M), increasing volatility risk on future updates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270538 |
Track record
21 reports on MGNX
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers